PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH GASTRIC ADENOCARCINOMA

PIYAKORN POONYAM | NATSUDA AUMPAN | RATHA-KORN VILAICHONE

GASTROENTEROLOGY UNIT, THAMMASAT UNIVERSITY HOSPITAL, PATHUMTHANI, THAILAND
DEPARTMENT OF MEDICINE, CHULABHORN INTERNATIONAL COLLEGE OF MEDICINE (CICM), THAMMASAT UNIVERSITY, PATHUMTHANI, THAILAND
DIGESTIVE DISEASES RESEARCH CENTER (DRC), THAMMASAT UNIVERSITY, PATHUMTHANI, THAILAND

Abstract

Background: Gastric cancer ranks as a leading cause of cancer deaths worldwide. Information of prognostic factors related to gastric cancer are limited.

Aim: This study aimed to gather clinical data and prevalence of prognostic factors related to gastric adenocarcinoma in Thailand.

Methods and results: This retrospective cohort study was conducted at Thammasat University Hospital, Thailand between January 2010 and July 2018. Gastric adenocarcinoma patients were enrolled and followed up for at least 5 years. Total of 210 gastric tumor patients were enrolled. One hundred patients were diagnosed with gastric adenocarcinomas (57 men and 43 women, mean age = 61.1 years). The leading presenting symptoms were weight loss (65%), followed by dyspepsia (54%) and UGI bleeding. Common clinical manifestations were thrombocytosis (26%), followed by syndrome of inappropriate antidiuretic hormone (SIADH; 15%). Eosinophilia was present in early cancer (25.0% vs 6.5%, \( P = .123 \)), while SIADH and thrombocytosis were more common in advanced stages (16.3% vs 0%, \( P = .602 \), and 28.3% vs 0%, \( P = .108 \), respectively). SIADH was significantly related to reduced 1-year survival rate compared to normal serum sodium levels (21.4% vs 71.4%, OR 0.109, 95% CI 0.024-0.497, \( P = .004 \)). Five-year survival rates were worse in patients with SIADH, but better in patients with eosinophilia compared to patients without these conditions (0% vs 27.8%, \( P = .058 \) and 20.0% vs 7.8%, \( P = .375 \), respectively).

Conclusion: Thrombocytosis and SIADH were common in gastric cancer. SIADH was significantly correlated with poor 1-year survival. These clinical manifestations might be useful for predicting gastric cancer prognosis.

KEYWORDS

gastric cancer, prognostic factors

1 INTRODUCTION

Gastric cancer is one of the most common cancers leading to cancer-related deaths worldwide. The GLOBOCAN database 2018 noted that more than 1 million people per year were newly diagnosed with gastric cancer. Most patients present at an advanced unresectable stage resulting in high mortality rate second only to lung cancer.1 Gastric cancer incidence varied among geographic regions. East Asian countries including the Republic of Korea and Japan have the highest incidence, whereas the rates are low in North America and Africa.1

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2020 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Thailand is the second largest country in mainland Southeast Asia with approximately 69 million people. The age-standardized incidence rate of gastric cancer in Thailand was relatively low (3.1 per 100 000) compared to other Asian countries (14.3 per 100 000). However, gastric cancer ranked ninth in cancer mortality due to its grave prognosis especially in younger patients. The majority of gastric cancers are adenocarcinomas.

*Helicobacter pylori*, a gram-negative rod-shaped bacterium, has been recognized as the most important factor associated with gastric cancer. *H. pylori* infection causes persistent gastric mucosal inflammation producing oxidative stress and DNA damage. Gastric glands subsequently undergo precancerous differentiation and eventually become malignant cells. *H. pylori* eradication is considered the most effective strategy to reduce the incidence of gastric cancer. Apart from bacterial factors, host genetic polymorphisms promoting an inflammatory response and environmental factors such as high dietary salt intake are linked to an increased risk of gastric cancer. In addition to avoiding modifiable risk factors, recognition of symptoms and signs is also important for cancer diagnosis. More than half of gastric cancer patients have predominant symptoms of weight loss (61.6%) and abdominal pain (51.6%). Some signs and symptoms may occur as a result from the immune response against malignant cells. Previous studies reported atypical clinical features such as abrupt onset of numerous seborheic keratoses (Leser-Trelat sign), and acanthosis nigricans in gastric cancer patients.

Until now, there have been few modern era reports about prognostic factors related to survival rate of gastric cancer patients. This study aimed to gather clinical data and prevalence of each prognostic factors related to gastric cancer in Thailand.

## Methods

### Study design

This retrospective cohort study was conducted at Thammasat University Hospital between January 2010 and July 2018. Patients underwent upper gastrointestinal endoscopy as indicated by Gastroenterology Association of Thailand (GAT). Gastric biopsies from a lesion suspicious for gastric cancer were then performed by gastroenterologists. The inclusion criteria were patients aged more than 18 years old with gastric adenocarcinoma diagnosed by histopathological results of gastric biopsies. Patients with incomplete medical records were excluded from the study. Demographic data, underlying diseases, clinical information, laboratory profiles such as complete blood count, tumor markers (CEA, CA 19-9), endoscopic features, histopathological results, current *H. pylori* infection status, complications, and treatment outcomes were extracted from medical records and retrospectively reviewed. Cancer staging was defined by TNM classification at the time of diagnosis. Long-term follow-up data of patients were monitored for at least 5 years after cancer diagnosis.

### Statistical analysis

The statistical analysis was performed by using SPSS version 22 (SPSS Inc, Chicago, Illinois). The demographic data were analysed by Fisher’s exact test, or Chi-square test where appropriate. *P*-value of less than .05 was defined as statistical significance. The study protocol was approved by the Human Research Ethics Committee of Thammasat University, Thailand and was conducted according to the good clinical practice guideline, as well as the Declaration of Helsinki.

## Results

A total of 210 gastric tumor patients were enrolled. One hundred patients were diagnosed with gastric adenocarcinomas (57 men and 43 women, mean age of 61.1 years). The most frequent comorbidities were hypertension (28%), followed by dyslipidemia (18%). The most common presenting symptoms of gastric adenocarcinomas were weight loss (65%), dyspepsia (54%), and upper gastrointestinal bleeding (males vs females: 22.8% vs 7.0%, OR 3.94, 95% CI 1.05-14.84, *P* = .033); the least common symptom was dysphagia (13%). Smoking was more common in men (32.6% vs 2.9%, OR 16.41, 95% CI 2.03-132.49, *P* = .009). The overall rate of active *H. pylori* infection in
gastric cancer patients was 46%. There was no patient with family history of gastric cancer. Intestinal-type gastric cancer was more prevalent than diffuse type in both genders (68.4% in men and 53.5% in women). The overall 1-year survival rate was 48.9%. The 1-year survival rate was slightly higher in men than women (51.0% vs 46.2%). Demographic data including gender, age, comorbidities, type of cancer, cancer staging, and 1-year survival rate are shown in Table 1.

The most common clinical manifestations related to gastric cancer were cancer cachexia (62%), followed by thrombocytosis (26%), SIADH (15%), and eosinophilia (8%) as demonstrated in Table 2. Hematologic manifestations were present in 37 patients including thrombocytosis, eosinophilia, leukocytosis, and venous thromboembolisms in 26 (70.2%), 8 (21.6%), 8 (21.6%), and 3 (8.1%) patients, respectively. Patients with other causes of reactive thrombocytosis such as infection, or iron deficiency anemia were excluded from paraneoplastic thrombocytosis. In the same way, leukocytosis and eosinophilia from other causes such as parasitic infection, or medication were excluded. Paraneoplastic thrombocytosis, hypercoagulability, and leukocytosis were present only in advanced-stage patients (28.3% vs 0%, \( P = .108 \), 3.3% vs 0%, \( P = 1.000 \), and 8.7% vs 0%, \( P = 1.000 \), respectively), while eosinophilia was more prevalent in early stage disease (25.0% vs 6.5%, \( P = .123 \)). Massive leukocytosis was a rare

| Characteristics | Male (N = 57) | Female (N = 43) | P value |
|-----------------|--------------|----------------|---------|
| Age (years ± SD) | 63.1 ± 15.2 | 58.4 ± 14.8 | .128 |
| BMI (kg/m² ± SD) | 19.1 ± 3.1 | 19.5 ± 4.6 | .705 |
| Comorbidities | | | |
| None | 28 (49.1%) | 29 (67.4%) | .067 |
| Diabetes mellitus | 8 (14.0%) | 7 (16.3%) | .756 |
| Hypertension | 20 (35.1%) | 8 (18.6%) | .069 |
| Dyslipidemia | 12 (21.1%) | 6 (14.0%) | .360 |
| Chronic kidney disease | 4 (7.0%) | 1 (2.3%) | .387 |
| Ischemic heart disease | 3 (5.3%) | 1 (2.3%) | .632 |
| Cerebrovascular accident | 5 (8.8%) | 1 (2.3%) | .233 |
| Chronic obstructive pulmonary disease | 2 (3.5%) | 0 (0%) | .505 |
| Cirrhosis | 8 (14.0%) | 5 (11.6%) | .723 |
| Clinical presentation | | | |
| Weight loss | 36 (63.2%) | 29 (67.4%) | .657 |
| Dyspepsia | 27 (47.4%) | 27 (62.8%) | .126 |
| Anorexia | 18 (31.6%) | 20 (46.5%) | .128 |
| Nausea and vomiting | 15 (26.3%) | 10 (23.3%) | .726 |
| Anemic symptoms | 15 (26.3%) | 12 (27.9%) | .859 |
| GI bleeding | 13 (22.8%) | 3 (7.0%) | .033 |
| Dysphagia | 5 (8.8%) | 8 (18.6%) | .148 |
| H. pylori infection | 25 (43.9%) | 21 (48.8%) | .621 |
| Family history of GI cancer | 5 (8.8%) | 3 (7.0%) | 1.000 |
| Smoking | 14 (23.8%) | 1 (2.9%) | .009 |
| Cancer type | | | |
| Intestinal type | 39 (68.4%) | 23 (53.5%) | .128 |
| Diffuse type | 18 (31.6%) | 20 (46.5%) | .128 |
| Cancer TNM staging | | | |
| Stage I | 2 (3.5%) | 1 (2.3%) | 1.000 |
| Stage II | 3 (5.3%) | 3 (7.0%) | 1.000 |
| Stage III | 17 (29.8%) | 18 (41.9%) | .212 |
| Stage IV | 35 (61.4%) | 21 (48.8%) | .210 |
| Cancer staging | | | |
| Early stage | 5 (8.8%) | 3 (7.0%) | 1.000 |
| Advanced stage | 52 (91.2%) | 40 (93.0%) | 1.000 |
| 1-year survival rate | 26/51 (51.0%) | 18/39 (46.2%) | .650 |
manifestation present in only one patient (i.e., a 35-year-old man with stage IV gastric adenocarcinoma and an absolute neutrophil count of 70,800 per mm$^3$). Three patients had malignant thrombosis according to hypercoagulable stage related to gastric cancer. One patient presented with bilateral pulmonary embolism and inferior mesenteric vein thrombosis. The second one had inferior vena cava thrombosis extending downwards to right common iliac vein. Another had deep vein thrombosis of left leg.

Hyponatremia from SIADH was present in 15% of patients. The mean plasma sodium level at initial presentation of patients with SIADH was lower than that of hyponatremia from other causes as demonstrated in Figure 1 (126.2 ± 2.7 vs 132.5 ± 1.3, $P < .001$). All patients with SIADH had advanced cancer. Hypercalcemia was also present in only advanced disease. Two patients with hypercalcemia died within 1 year (3 and 9 months) after diagnosis.

Disease outcomes within the first year after diagnosis could be evaluated in 90 patients as 10 (10%) were lost to follow-up. Risk factors associated with mortality rate within 1 year are shown in Table 3. Mortality rate within 1 year after diagnosis was higher in advanced cancer than early disease (54.2% vs 14.3%, OR 7.11, 95% CI 0.82-61.65, $P = .075$). Gender, age, and comorbidities did not exhibit significant associations with one-year mortality rate. Anorexia was significantly associated with higher mortality rate within 1 year (67.6% vs 39.6%, OR 3.42, 95% CI 1.32-8.86, $P = .011$). SIADH was the only manifestation significantly related to lower 1-year survival rate compared to normal serum sodium levels (21.4% vs 71.4%, OR 0.109, 95% CI 0.0109-0.497, $P = .004$) as demonstrated in Figure 2. The median survival time of gastric cancer patients with SIADH was 145 days (IQR 91-315).

There were 69 patients included for estimating the 5-year survival rate. Six patients were alive after diagnosis for 5 years. Patients with early cancer had superior 5-year survival rate to advanced cancer (66.7% vs 61.0%, OR 31.0, 95% CI 2.29-419.35, $P = .01$). Five-year survival rates were worse in patients with SIADH, but better in patients with eosinophilia compared to patients without these conditions (0% vs 27.8%, $P = .058$ and 20.0% vs 7.8%, $P = .375$, respectively). One-year and five-year survival rates classified by sodium level and prognostic factors were demonstrated in Figures 2 and 3, respectively.

**DISCUSSION**

Gastric cancer has ranked as the second leading cause of global cancer mortality for more than 30 years. The global database revealed over 1 million new cases and approximately 783,000 deaths attributed to stomach cancer annually.\(^1\) Although the incidence and mortality rate remain high, there has been a decline in cancer mortality over the past 90 years.\(^17\) Reduction in gastric cancer mortality are explained in part by the discovery and eradication of *H. pylori* which is a significant risk factor for development of gastric cancer.\(^18\) In addition, the invention of electric refrigerators in the mid-19th century improved quality of food storage by decreasing salt-based food preservation and bacterial contamination.\(^19\) Thailand is the Southeast Asian country with low gastric cancer incidence (2.3%), but high *H. pylori* infection and its mortality rate is still high positioning in the ninth place of national cancer death statistics.\(^20\) Patients with gastric adenocarcinomas in this study demonstrated the usual male to female predominance with the ratio of 1.33 to 1 although the ratio was slightly lower than the previous study in Thailand and other countries.\(^17,21\) Although previous studies observed protective effects of estrogen on gastric cancer, there was no difference in 1-year survival rate between genders in this study.\(^22,23\) Considering risk factors for gastric cancer, our study demonstrated no difference of *H. pylori* infection between gender and significantly higher history of smoking in males. Overall prevalence of

### TABLE 2 Clinical manifestations classified by gender and stage of cancer

| Factors        | Total (N = 100) | Male (N = 57) | Female (N = 43) | P-value | Early (N = 8) | Advanced (N = 92) | P-value |
|---------------|----------------|--------------|----------------|---------|--------------|------------------|---------|
| Cachexia      | 62             | 36 (63.2%)   | 26 (60.5%)     | .784    | 1 (12.5%)    | 61 (66.3%)       | .016    |
| Hematologic system | 37            | 20 (35.1%)   | 17 (39.5%)     | .648    | 2 (25.0%)    | 35 (38.0%)       | .469    |
| Thrombocytosis | 26             | 13 (22.8%)   | 13 (30.2%)     | .402    | 0            | 26 (28.3%)       | .108    |
| Hypercoagulability | 3             | 1 (1.8%)     | 2 (4.7%)       | .576    | 0            | 3 (3.3%)         | 1.000   |
| Leukocytosis   | 8              | 2 (3.5%)     | 6 (14.0%)      | .072    | 0            | 8 (8.7%)         | 1.000   |
| Eosinophilia   | 8              | 5 (8.8%)     | 3 (7.0%)       | 1.000   | 2 (25.0%)    | 6 (6.5%)         | .123    |
| Endocrine system | 16            | 6 (10.5%)    | 10 (23.3%)     | .086    | 0            | 16 (17.4%)       | .348    |
| SIADH          | 15             | 6 (10.5%)    | 9 (20.9%)      | .149    | 0            | 15 (16.3%)       | .602    |
| Hypercalcemia  | 2              | 1 (1.8%)     | 1 (2.3%)       | 1.000   | 0            | 2 (2.2%)         | 1.000   |

Abbreviation: SIADH, syndrome of inappropriate antidiuretic hormone.

**FIGURE 1** The box plot of plasma sodium level
Current H. pylori infection in gastric cancer patients was 46% which was comparable to the previous study.24 The earlier study conducted in 10 European countries with low incidence of gastric cancer demonstrated that both current and former smokers were at higher risk of development of gastric cancer.25 The two most common presenting symptoms were weight loss (65%) and dyspepsia (54%) same

TABLE 3 Univariate and multivariate analyses for risk factors associated with mortality rate within 1 year of gastric cancer patients

| Variables           | Univariate analysis | Multivariate analysis |
|---------------------|---------------------|-----------------------|
|                     | OR  (95% CI)        | P-value       | OR  (95% CI) | P-value   |
| Male gender         | 0.82 (0.36-1.90)    | .650         |             |           |
| Age >60 years       | 1.09 (0.48-2.49)    | .837         |             |           |
| Comorbidities       | 1.01 (0.44-2.33)    | .977         |             |           |
| FH of GI cancer     | 1.67 (0.37-7.44)    | .503         |             |           |

Clinical presentation
- Weight loss: 1.18 (0.50-2.82) .708
- Dyspepsia: 1.56 (0.67-3.61) .302
- Anorexia: 3.18 (1.32-7.66) .010
- Nausea and vomiting: 1.37 (0.51-3.67) .529
- Anemic symptoms: 0.75 (0.29-1.91) .546
- GL bleeding: 0.68 (0.21-2.13) .503
- Dysphagia: 0.50 (0.14-1.86) .303

Cancer type
- Intestinal type: 1
- Diffuse type: 0.96 (0.40-2.30) .927

Cancer staging
- Advanced stage: 7.11 (0.82-61.65) .075
- Cachexia: 1.07 (0.46-2.52) .869

Hematological lab values
- Leukocytosis (>11 000/μL): 1.30 (0.27-6.18) .740
- Eosinophilia (>500/μL): 0.36 (0.07-1.93) .231
- Thrombocytosis (>400 000/μL): 1.31 (0.52-3.32) .565

Plasma sodium level
- Normonatremia (≥135 mEq/L): 1
- Hyponatremia from other causes: 3.21 (1.18-8.73) .022
- SIADH: 9.17 (2.01-41.80) .004

Abbreviation: SIADH, syndrome of inappropriate antidiuretic hormone.

FIGURE 2 The 1-year and 5-year survival rates between groups according to sodium level

FIGURE 3 One-year and five-year survival rates classified by prognostic factors
as the prior report. In our study, 16% of patients presented with upper gastrointestinal bleeding which was comparable to the previous report. However, the previous study did not mention patients presenting symptoms classified by gender. Furthermore, this study indicated that upper gastrointestinal bleeding as a clinical presentation in men significantly higher than women (22.8% vs 7.0%, OR 3.94, 95% CI 1.05-14.84, P = .033). Apart from presenting symptoms, the important findings of this study highlighted common manifestations in gastric cancer patients and might have an impact on patient’s prognosis.

This study documented possible manifestations of various organ systems which developed in patients with gastric cancer. The most common clinical manifestation was cancer cachexia which was comparable to the previous study. Almost half of cancer patients presenting with cachexia had poor outcomes. The pathogenesis of cancer cachexia involves in tumor-secreted cytokines stimulating hypothalamic response and subsequently leading to anorexia. Moreover, cytokines can potentiate catabolic state resulting in increased energy consumption along with protein breakdown and eventually cause reduced muscle mass.

Thrombocytosis was the most frequent hematologic manifestation (26%) which was higher than prior studies in East Asian countries (6.4%-11.4%). This might be explained by greater number of advanced-stage patients in this study than other countries. The mechanisms of paraneoplastic thrombocytosis occurred by production of several cytokines such as interleukin-1 (IL-1), IL-6, and IL-11 in malignant solid tumors. IL-6 overproduced by gastric cancer mediated the induction of hepatic thrombopoietin (TPO) mRNA expression resulting in rising of TPO level and consequently increasing a platelet count. Elevation of platelet count found only in patients with advanced gastric cancer could be correlated to poor prognosis. However, there was no significant difference of survival rates between groups having thrombocytosis and normal platelet numbers. Apart from thrombocytosis, a hypercoagulable state can be caused by several mechanisms including procoagulant activity expressed by both normal human cells and cancer procoagulant itself. Venous thromboembolism (VTE) was established from hypercoagulable state associated with gastric cancer. All three patients having VTE were diagnosed with advanced-stage gastric cancer. Two of them survived more than 1 year after diagnosis. The previous study revealed overall survival within VTE group of approximately 12 months and also stated that advanced disease with VTE contributed to almost three times higher mortality rates than early cancer without VTE.

The second most common hematologic abnormalities were eosinophilia and leukocytosis. The prevalence of eosinophilia in this study was 8%. Patients experiencing eosinophilia were more likely to have early-stage than advanced cancer. Moreover, both 1-year and 5-year survival rates of patients with eosinophilia were higher than patients with normal eosinophil count. This might be explained by anti-tumorigenic factors, for example, TNF-α, granzyme, and cationic proteins generated from eosinophils. The study in 1986 observed that eosinophilic infiltration in gastric tumors significantly corresponding to blood eosinophilia was a good prognostic marker for prolonged survival rate of patients with gastric cancer. In addition, the reappearance of eosinophilia was noted in patients with recurrent gastric cancer. On the contrary, there were a few case reports describing massive eosinophilia in advanced gastric cancers contributing to poor prognosis. Leukocytosis was another hematologic manifestation presented in eight patients after excluding causes of infection, inflammation, medications, or myeloproliferative neoplasms. Some studies exhibited hyperleukocytosis as an uncommon paraneoplastic syndrome in advanced pancreatic adenocarcinoma and soft tissue sarcoma. These rare events were caused by excessive secretion of granulocyte colony-stimulating factor and associated with poor prognosis. However, there was no previous report of this condition in gastric cancer patients.

Electrolyte abnormalities caused by endocrine disorders were present in gastric cancer patients. Hyponatremia from SIADH was evidently demonstrated only in advanced disease. This study demonstrated significantly lower 1-year survival rate in patients with SIADH. No patients with SIADH survived after 5 years of diagnosis. The median survival time was less than 1 year in SIADH group designating poor prognosis possibly related to this condition. Until now, there has been no report about prevalence and prognosis of SIADH in gastric cancer patients. Two case reports demonstrated patients presenting with symptomatic hyponatremia with the initial plasma sodium level of less than 130 mEq/L. The prior study indicated that terminal cancer was associated with hyponatremia and also mentioned that the lower the sodium level was, the shorter survival time the patient had left. Our study reported two patients with hypercalcemia diagnosed with advanced stage gastric cancer and subsequently died within 1 year after diagnosis. Hypercalcemia in gastric cancer might be a grave prognostic factor in this particular disease.

5 | CONCLUSION

Gastric cancer is an important cause of cancer mortality worldwide. Smoking and upper GI bleeding were significantly common among men with gastric cancer. Thrombocytosis and SIADH were common in gastric cancer. SIADH was significantly correlated with poor 1-year survival. These clinical manifestations might be useful for predicting gastric cancer prognosis.

ETHICS STATEMENT

The study received ethical approval by the Human Research Ethics Committee of Thammasat University, Thailand and was conducted according to the good clinical practice guideline, as well as the Declaration of Helsinki. The project number of ethical approval was MTU-EC-IM-2-160/61. All data had been fully anonymized before they were accessed. The Ethics Committee waived the requirement for informed consent because of no greater than minimal risk for participants.

ACKNOWLEDGMENTS

The authors thank Dr. David Y. Graham for his comments and editorial assistance. This study was supported by Bualuang ASEAN Chair Professorship at Thammasat University, Digestive Diseases Research Center (DRC), Thammasat University, Thailand.
AUTHOR CONTRIBUTIONS
Piyakorn Poonyam: Data curation; formal analysis; resources; writing-original draft. Natsuda Aumpan: Formal analysis; writing-original draft; writing-review and editing.

CONFLICT OF INTEREST
The authors declare that they have no conflict of interest.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Ratha-Korn Vilaichone https://orcid.org/0000-0003-4298-9331

REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
2. Subsomwong P, Miftahussurur M, Uchida T, et al. Prevalence, risk factors, and virulence genes of Helicobacter pylori among dyspeptic patients, in two different gastric cancer risk regions of Thailand. PLoS One. 2017;12:e0187113.
3. Punjachaipornpon T, Mahachai V, Vilaichone RK. Severe manifestations and grave prognosis in young patients with gastric cancer in Thailand. Asian Pac J Cancer Prev. 2016;17:3427-3429.
4. Nanthananangkul S, Suwanungrueng K, Wiangnon S, Promthet S. Survival of stomach cancer cases in Khon Kaen, Thailand 2000-2012. Asian Pac J Cancer Prev. 2016;17:2125-2129.
5. Quach DT, Vilaichone RK, Vu KV, Yamaoka Y, Sugano K, Mahachai V. Helicobacter pylori infection and related gastrointestinal diseases in southeast Asian countries: an expert opinion survey. Asian Pac J Cancer Prev. 2018;19:3565-3569.
6. Aumpun N, Vilaichone RK, Gammaaral P, et al. Prevalence and antibiotic resistance patterns of Helicobacter pylori infection in Koh Kong, Cambodia. Asian J Cancer Prev. 2020;21:1409-1413.
7. Vilaichone RK, Wongcha Um A, Chotivitayatarakorn P. Low re-infecion rate of Helicobacter pylori after successful eradication in Thailand: a 2 years study. Asian Pac J Cancer Prev. 2017;18:695-697.
8. Correa P, Piazuelo MB. The gastric precancerous cascade. J Dig Dis. 2012;13:2-9.
9. Mahachai V, Vilaichone RK, Pittayanon R, et al. Thailand consensus on Helicobacter pylori treatment 2015. Asian Pac J Cancer Prev. 2016;17:2351-2360.
10. Vilaichone RK, Aumpun N, Ratanauch-Ek T, et al. Efficacy of omeprazole, tetracycline, and 4 times daily dosing of amoxicillin in Helicobacter pylori eradication in limited resource area in Bhutan: a prospective randomized trial (Bhutan study). Asian Pac J Cancer Prev. 2020;21:1109-1114.
11. Gora V. Etiopathogenesis of gastric cancer. Asian Pac J Cancer Prev. 2016;17:2745-2750.
12. Raeli N, Behrouz B, Zahri S, Latifi-Navid S. Helicobacter pylori infection and dietary factors act synergistically to promote gastric cancer. Asian Pac J Cancer Prev. 2016;17:917-921.
13. Wanebo HJ, Kennedy BJ, Chmiel J, Steele G Jr, Winchester D, Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 1993;218:583-592.
14. Kameya S, Noda A, Isobe E, Watanabe T. The sign of Leser-Trelat associated with carcinoma of the stomach. Am J Gastroenterol. 1988;83:664-666.
15. Yu Q, Li XL, Ji G, et al. Malignant acanthosis nigricans: an early diagnostic clue for gastric adenocarcinoma. World J Surg Oncol. 2017;15:208.
16. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489-495.
17. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12:354-362.
18. Kumar S, Metz DC, Ellenberg S, et al. Risk factors and incidence of gastric cancer after detection of Helicobacter pylori infection: a large cohort study. Gastroenterology. 2020;158:527-536.
19. La Vecchia C, Negri E, D’Avanzo B, et al. Electric refrigerator use and gastric cancer risk. Br J Cancer. 1990;62:136-137.
20. World Health Organization. Thailand: GLOBOCAN 2018. World Health Organization [Internet]. 2019. http://gco.iarc.fr/today/data/factsheets/populations/764-thailand-fact-sheets.pdf. Accessed March 10, 2020.
21. Thong-Ngam D, Tangkijvanich P, Mahachai V, Kulavanijaya P. Current status of gastric cancer in Thai patients. J Med Assoc Thai. 2001;84:475-482.
22. Ur Rahman MS, Cao J. Estrogen receptors in gastric cancer: advances and perspectives. World J Gastroenterol. 2016;22:2475-2482.
23. Nie X, Xie R, Tuo B. Effects of estrogen on the gastrointestinal tract. Dig Dis Sci. 2018;63:583-596.
24. Forman D. The prevalence of Helicobacter pylori infection in gastric cancer. Aliment Pharmacol Ther. 1995;9:71-76.
25. Gonzalez CA, Pera G, Agudo A, et al. Smoking and the risk of gastric cancer in the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer. 2003;107:629-634.
26. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern cooperative oncology group. Am J Med. 1980;69:491-497.
27. Mondello P, Mian M, Aloisi C, Farni F, Mondello S, Pitini V. Cancer cachexia syndrome: pathogenesis, diagnosis, and new therapeutic options. Nutr Cancer. 2015;67:12-26.
28. Hwang SG, Kim KM, Cheong JH, et al. Impact of pretreatment thrombocytosis on blood-borne metastasis and prognosis of gastric cancer. Eur J Surg Oncol. 2012;38:562-567.
29. Ikeda M, Furukawa H, Imamura H, et al. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol. 2002;9:287-291.
30. Lu RJ, Afshar-Kharghan V, Schafer AI. Paraneoplastic thrombocytosis: the secrets of tumor self-promotion. Blood. 2014;124:184-187.
31. Wu CW, Wang SR, Chao MF, et al. Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol. 1996;91:1417-1422.
32. Kaser A, Brandacher G, Steurer W, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood. 2001;98:2720-2725.
33. Li FX, Wei LJ, Zhang H, Li SX, Liu JT. Significance of thrombocytosis in clinicopathologic characteristics and prognosis of gastric cancer. Asian Pac J Cancer Prev. 2014;15:6511-6517.
34. Fuentes HE, Oramas DM, Paz LH, Wang Y, Andrade XA, Tafur AJ. Venous thromboembolism is an independent predictor of mortality among patients with gastric cancer. J Gastrointest Cancer. 2018;49:415-421.
35. Varrichio G, Galdiero MR, Loffredo S, et al. Eosinophils: the unsung heroes in cancer? Onco Targets Ther. 2018;7:e1393134.
36. Iwasaki K, Torisu M, Fujimura T. Malignant tumor and eosinophils. I. Prognostic significance in gastric cancer. Cancer. 1986;58:1321-1327.
37. Tsutsui Y, Ohshita T, Tokoyama T. A case of gastric carcinoma with massive eosinophilia. Acta Pathol Jpn. 1984;34:117-122.
38. Takeda H, Nishikawa H, Tsumura T, et al. Prominent hyper-eosinophilia with disseminated intravascular coagulation as an unusual presentation of advanced gastric cancer. Intern Med. 2014;53:563-569.
39. Wu ES, Srour SA. Paraneoplastic Hyperleukocytosis in pancreatic adenocarcinoma. J Pancreat Cancer. 2017;3:84-86.
40. Dorn C, Bugl S, Malenke E, et al. Paraneoplastic granulocyte colony-stimulating factor secretion in soft tissue sarcoma mimicking myeloproliferative neoplasia: a case report. BMC Res Notes. 2014;7:313.
41. Hwang K, Jeon DH, Jang HN, et al. Inappropriate antidiuretic hormone syndrome presenting as ectopic antidiuretic hormone-secreting gastric adenocarcinoma: a case report. J Med Case Reports. 2014;8:185.
42. Pai A, Pervin S. Unusual paraneoplastic syndrome of inappropriate antidiuretic hormone secretion with gastric cancer. Int J Res Med Sci. 2019;7:3192.
43. Yoon J, Ahn SH, Lee YJ, Kim CM. Hyponatremia as an independent prognostic factor in patients with terminal cancer. Support Care Cancer. 2015;23:1735-1740.
44. Kumar M, Kumar A, Kumar V, Kaur S, Maroules M. Hypercalcemia as initial presentation of metastatic adenocarcinoma of gastric origin: a case report and review of the literature. J Gastric Cancer. 2016;16:191-194.
45. Nakajima K, Tamai M, Okaniwa S, et al. Humoral hypercalcemia associated with gastric carcinoma secreting parathyroid hormone: a case report and review of the literature. Endocr J. 2013;60:557-562.

How to cite this article: Poonyam P, Aumpan N, Vilaichone R-K. Prognostic factors for survival in patients with gastric adenocarcinoma. Cancer Reports. 2021;4:e1305. https://doi.org/10.1002/cnr2.1305